Obesity affects over a third of the global population and is a major risk factor for numerous chronic diseases. To find ...

A study by the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) reveals that inflammation ...

BOSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients ...

A panelist discusses how axatilimab, a humanized IgG4 monoclonal antibody targeting CSF-1 receptors on monocytes and macrophages, showed promising results in the AGAVE-201 trial for ...

A study reveals that inflammation associated with Marfan syndrome increases vulnerability to neurological diseases and complications following strokes, as demonstrated in animal models.

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced positive top-line Phase II study results for its novel ...

Panelists discuss how investigational therapies beyond Janus kinase (JAK) inhibition, including epigenetic modulation, telomerase inhibition, PI3K/AKT/mTOR pathway inhibition, immune modulation, TGF-β ...

New research highlights myostatin inhibition as a powerful strategy to combat osteoporosis and sarcopenia. Learn how ...

A pioneering research study published today in Cell Metabolism details how the hormone FGF21 (fibroblast growth factor 21) can reverse the effects of fatty liver disease in mice. The hormone works ...

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Tribeca Global Natural Resources Limited (TGF). However, you won't necessarily see their names ...

The cancer microenvironment, or tumour microenvironment, describes the non-cancerous cells present in the tumour. These include fibroblasts, immune cells and cells that comprise the blood vessels ...

ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has a robust pipeline ...